Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK Pharma Q1 net...

    GSK Pharma Q1 net profit up 35 percent at Rs 113 crore in FY20

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-23T09:45:39+05:30  |  Updated On 23 July 2019 9:45 AM IST
    GSK Pharma Q1 net profit up 35 percent at Rs 113 crore in FY20

    Mumbai: GlaxoSmithKline (GSK) Pharmaceuticals on Monday announced a 35 per cent jump in its net profit to Rs 113.5 crore during the first quarter of current fiscal from Rs 88.6 crore in the corresponding quarter ended June 30 last year.


    The total income also rose by 7 per cent to Rs 818 crore as against Rs 753 crore in the same period. At the same time, total expenses increased from Rs 607 crore to Rs 642 crore.


    Read Also: GSK to appoint Novartis, Astrazeneca ex-executive Jonathan Symonds as new Chairman: Bloomberg


    Profit before tax in Q1 FY20 was Rs 176 crore compared to Rs 138 crore in Q1 of FY19, the company said in a statement.


    The earnings per share of Rs 10 each works out to Rs 6.70 in the quarter ended June 30 compared to Rs 5.23 in the first quarter of the previous year.


    Read Also: GSK drug Zejula helps ovarian cancer patients live longer in late-stage study


    GlaxoSmithKline Pharmaceuticals business has been serving healthcare needs in India for more than 90 years. It has a wide range of prescription medicines across areas covering anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases.


    Read Also: GSK to fund doctoral programs at Government established Regional Centre for Biotechnology
    Cardiovascular diseaseDermatologydiabetesGlaxoSmithKlineGSKGSK PharmaGynecologyoncologypharmapharma companypharma newsQ1FY20respiratory diseases
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok